|

LS301-IT 0.1 mg/kg Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 2: 1

Top Sponsors

  • Integro Theranostics1

Indications

  • Non-small Cell Lung Cancer (NSCLC)1
  • Lung Cancer1
  • Cancer1

Philadelphia, Pennsylvania1 trial

Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer

University of Pennsylvania

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.